GlucoTrack Submits FDA Application for New Glucose Monitoring Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Source: Newsfilter
GlucoTrack Inc. shares fell 14.46% and hit a 20-day low amid broader market gains, with the Nasdaq-100 up 0.96% and the S&P 500 up 0.56%.
The decline comes despite GlucoTrack's recent submission of an Investigational Device Exemption (IDE) application to the FDA for its Continuous Blood Glucose Monitoring (CBGM) technology. This submission marks a significant advancement in the company's clinical research efforts, aiming to provide a new monitoring option for diabetes patients. The company plans to initiate a U.S. clinical study post-FDA review and approval, which could validate the technology's effectiveness and safety.
This FDA application represents a crucial step for GlucoTrack, as the potential approval of its implantable glucose monitoring system could significantly impact the diabetes management market, despite the current stock decline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GCTK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GCTK
About GCTK
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Glucotrack Reports Reduced Net Loss in Q1 2026
- Reduced Net Loss: In Q1 2026, Glucotrack reported a net loss of $4.3 million, a significant decrease from the $6.8 million loss in Q1 2025, indicating improvements in cost control and operational efficiency.
- Cash Position: As of March 31, 2026, the company's cash and cash equivalents stood at $3.9 million, down from $7.4 million as of December 31, 2025, reflecting some pressure on the company's financial management.
- Year-over-Year Comparison: While the reduction in net loss is positive, the decline in cash reserves may impact the company's short-term operational capacity, necessitating close attention to future financing strategies and cash flow management.
- Strategic Reevaluation Needed: With decreasing cash flow, Glucotrack may need to reassess its business strategy to ensure sustainable growth and profitability in a competitive market environment.
See More
Glucotrack Submits FDA Application to Advance Continuous Blood Glucose Monitoring Technology
- FDA Application Submitted: Glucotrack successfully submitted its Investigational Device Exemption (IDE) application to the FDA for its fully implantable Continuous Blood Glucose Monitoring (CBGM) technology, marking a key milestone towards initiating U.S. clinical trials in the second half of 2026, which is expected to propel the clinical evaluation of its technology.
- Clinical Data Validation: The company published two peer-reviewed articles in the IEEE Sensors Journal and The Journal of Diabetes Research, validating the long-term stability and accuracy of its glucose sensor, with a reported 6.8% Mean Absolute Relative Difference (MARD), providing scientific evidence for the clinical application of the CBGM technology.
- Financial Position Improvement: In the first quarter, the company significantly improved its financial position by reducing the outstanding balance of its $3.6 million promissory note to approximately $1.6 million, while also drawing approximately $1.0 million from its existing equity line of credit, enhancing its operational cash flow sustainability.
- Increased R&D Expenses: Research and development expenses for Q1 2026 were $2.1 million, up from $1.9 million in Q1 2025, primarily due to timing changes in product and manufacturing development activities, reflecting the company's ongoing commitment to technology development.
See More
Glucotrack Submits FDA Application to Advance Blood Glucose Monitoring Technology
- Technological Advancement: Glucotrack has submitted its Investigational Device Exemption (IDE) application for its fully implantable Continuous Blood Glucose Monitoring (CBGM) technology, marking a significant step in the company's clinical research efforts and aiming to provide a new monitoring option for diabetes patients.
- Clinical Study Plans: The submission follows years of engineering and preclinical evaluation, with Glucotrack planning to initiate a U.S. clinical study post-FDA review and approval, aimed at validating the technology's effectiveness and safety.
- User Experience Enhancement: The implantable solution is designed to be comfortable and discreet, allowing patients to live their daily lives without frequent sensor changes or visible wearables, thereby improving quality of life and reducing medical intervention disruptions.
- Market Potential: With a sensor longevity of three years and minimal calibration requirements, Glucotrack's CBGM system, if approved, could capture a significant share of the diabetes management market, addressing the growing needs of patients.
See More
GlucoTrack Reports Narrowed Net Loss for 2025 Fiscal Year
- Improved Financial Performance: GlucoTrack reported a narrowed net loss of $19.4 million for 2025, down from $22.6 million in 2024, indicating progress in cost control and operational efficiency, which enhances investor confidence.
- Cash Flow Position: As of December 31, 2025, the company had $5.6 million in cash and cash equivalents, expected to be sufficient to fund its 2026 operating plan, ensuring IDE submission and initiation of U.S. clinical trials by late Spring.
- Clinical Research Progress: GlucoTrack initiated a long-term multicenter feasibility study in Australia to evaluate the performance and safety of its CBGM product, identifying product improvements based on early learnings, thereby enhancing market competitiveness.
- Accelerated FDA Communication: The company plans to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026 and initiate a human clinical feasibility study in the second half of 2026, indicating proactive regulatory engagement that could expedite product market entry.
See More
Glucotrack Files IDE for Innovative CBGM Technology
- Patent Portfolio Strengthened: Glucotrack has received three new patents from the USPTO that protect key innovations in its long-term implantable continuous blood glucose monitoring technology, thereby enhancing the company's intellectual property portfolio and improving its competitive position in the market.
- Successful Fundraising: The company completed a $4.0 million private placement, selling 1,033,591 shares of common stock and warrants for an additional 2,067,182 shares, which is expected to be used for working capital and general corporate purposes, thereby strengthening the company's financial foundation.
- Clinical Trial Plans: Glucotrack plans to launch its U.S. clinical trial in the second half of 2026, with an IDE submission expected in Q2 2026 to evaluate the safety and efficacy of its CBGM product, marking a significant step towards bringing its innovative technology to market.
- Increased R&D Spending: Research and development expenses for 2025 were $9.8 million, up from $9.5 million in 2024, reflecting the company's ongoing investment in product design and development, while the net loss decreased, demonstrating a strong commitment to technological advancement.
See More
Glucotrack Reports Q4 2025 Financial Results
- Financial Performance: Glucotrack reported a GAAP EPS of -$31.22 for Q4 2025, indicating significant challenges in profitability that could impact investor confidence.
- Cash Flow Status: As of December 31, 2025, the company had $7.4 million in cash and cash equivalents, up from $5.6 million in 2024, reflecting a net increase of $1.8 million due to $17.0 million from financing activities, offset by $15.3 million used in operating and investing activities.
- Funding Plans: The company believes its existing cash and cash equivalents will be sufficient to fund its 2026 operating plan, with plans to submit an IDE application and initiate U.S. human clinical trials by the end of Spring, which is crucial for future product development.
- Impact of Financing Activities: Although the company secured $17.0 million through financing, the substantial cash outflow of $15.3 million raises concerns about its overall financial health and may limit future growth potential.
See More
Glucotrack Reports Reduced Net Loss in Q1 2026
- Reduced Net Loss: In Q1 2026, Glucotrack reported a net loss of $4.3 million, a significant decrease from the $6.8 million loss in Q1 2025, indicating improvements in cost control and operational efficiency.
- Cash Position: As of March 31, 2026, the company's cash and cash equivalents stood at $3.9 million, down from $7.4 million as of December 31, 2025, reflecting some pressure on the company's financial management.
- Year-over-Year Comparison: While the reduction in net loss is positive, the decline in cash reserves may impact the company's short-term operational capacity, necessitating close attention to future financing strategies and cash flow management.
- Strategic Reevaluation Needed: With decreasing cash flow, Glucotrack may need to reassess its business strategy to ensure sustainable growth and profitability in a competitive market environment.
See More
Glucotrack Submits FDA Application to Advance Continuous Blood Glucose Monitoring Technology
- FDA Application Submitted: Glucotrack successfully submitted its Investigational Device Exemption (IDE) application to the FDA for its fully implantable Continuous Blood Glucose Monitoring (CBGM) technology, marking a key milestone towards initiating U.S. clinical trials in the second half of 2026, which is expected to propel the clinical evaluation of its technology.
- Clinical Data Validation: The company published two peer-reviewed articles in the IEEE Sensors Journal and The Journal of Diabetes Research, validating the long-term stability and accuracy of its glucose sensor, with a reported 6.8% Mean Absolute Relative Difference (MARD), providing scientific evidence for the clinical application of the CBGM technology.
- Financial Position Improvement: In the first quarter, the company significantly improved its financial position by reducing the outstanding balance of its $3.6 million promissory note to approximately $1.6 million, while also drawing approximately $1.0 million from its existing equity line of credit, enhancing its operational cash flow sustainability.
- Increased R&D Expenses: Research and development expenses for Q1 2026 were $2.1 million, up from $1.9 million in Q1 2025, primarily due to timing changes in product and manufacturing development activities, reflecting the company's ongoing commitment to technology development.
See More
Glucotrack Submits FDA Application to Advance Blood Glucose Monitoring Technology
- Technological Advancement: Glucotrack has submitted its Investigational Device Exemption (IDE) application for its fully implantable Continuous Blood Glucose Monitoring (CBGM) technology, marking a significant step in the company's clinical research efforts and aiming to provide a new monitoring option for diabetes patients.
- Clinical Study Plans: The submission follows years of engineering and preclinical evaluation, with Glucotrack planning to initiate a U.S. clinical study post-FDA review and approval, aimed at validating the technology's effectiveness and safety.
- User Experience Enhancement: The implantable solution is designed to be comfortable and discreet, allowing patients to live their daily lives without frequent sensor changes or visible wearables, thereby improving quality of life and reducing medical intervention disruptions.
- Market Potential: With a sensor longevity of three years and minimal calibration requirements, Glucotrack's CBGM system, if approved, could capture a significant share of the diabetes management market, addressing the growing needs of patients.
See More
GlucoTrack Reports Narrowed Net Loss for 2025 Fiscal Year
- Improved Financial Performance: GlucoTrack reported a narrowed net loss of $19.4 million for 2025, down from $22.6 million in 2024, indicating progress in cost control and operational efficiency, which enhances investor confidence.
- Cash Flow Position: As of December 31, 2025, the company had $5.6 million in cash and cash equivalents, expected to be sufficient to fund its 2026 operating plan, ensuring IDE submission and initiation of U.S. clinical trials by late Spring.
- Clinical Research Progress: GlucoTrack initiated a long-term multicenter feasibility study in Australia to evaluate the performance and safety of its CBGM product, identifying product improvements based on early learnings, thereby enhancing market competitiveness.
- Accelerated FDA Communication: The company plans to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026 and initiate a human clinical feasibility study in the second half of 2026, indicating proactive regulatory engagement that could expedite product market entry.
See More
Glucotrack Files IDE for Innovative CBGM Technology
- Patent Portfolio Strengthened: Glucotrack has received three new patents from the USPTO that protect key innovations in its long-term implantable continuous blood glucose monitoring technology, thereby enhancing the company's intellectual property portfolio and improving its competitive position in the market.
- Successful Fundraising: The company completed a $4.0 million private placement, selling 1,033,591 shares of common stock and warrants for an additional 2,067,182 shares, which is expected to be used for working capital and general corporate purposes, thereby strengthening the company's financial foundation.
- Clinical Trial Plans: Glucotrack plans to launch its U.S. clinical trial in the second half of 2026, with an IDE submission expected in Q2 2026 to evaluate the safety and efficacy of its CBGM product, marking a significant step towards bringing its innovative technology to market.
- Increased R&D Spending: Research and development expenses for 2025 were $9.8 million, up from $9.5 million in 2024, reflecting the company's ongoing investment in product design and development, while the net loss decreased, demonstrating a strong commitment to technological advancement.
See More
Glucotrack Reports Q4 2025 Financial Results
- Financial Performance: Glucotrack reported a GAAP EPS of -$31.22 for Q4 2025, indicating significant challenges in profitability that could impact investor confidence.
- Cash Flow Status: As of December 31, 2025, the company had $7.4 million in cash and cash equivalents, up from $5.6 million in 2024, reflecting a net increase of $1.8 million due to $17.0 million from financing activities, offset by $15.3 million used in operating and investing activities.
- Funding Plans: The company believes its existing cash and cash equivalents will be sufficient to fund its 2026 operating plan, with plans to submit an IDE application and initiate U.S. human clinical trials by the end of Spring, which is crucial for future product development.
- Impact of Financing Activities: Although the company secured $17.0 million through financing, the substantial cash outflow of $15.3 million raises concerns about its overall financial health and may limit future growth potential.
See More
